Condition

Advanced Gastric Cancer

ClinicalTrials.gov condition label

Clinical trials9

Recruiting3

Common interventions21

Lead sponsors shown9

Clinical trials

9 shown

Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful BiomarkersNCT07259226 · 2025-11-14

Evaluation of the Effectiveness of Managing Chemotherapy Side Effects Using ePRO and a Standardized Telenursing Program for Cancer PatientsNCT07405931 · 2025-07-09

HS-10502 Combination Treatment in Patients With Advanced Solid TumorsNCT06769425 · 2025-05-07

A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or AmplificationNCT06585488 · 2024-12-13

A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid TumorsNCT06157892 · 2024-05-20

ACTIVE_NOT_RECRUITING

IMM2902, a HER2/SIRPα Bispecific MAb-Trap Antibody-receptor Fusion Protein, in Patients with HER2-expressing Advanced Solid TumorsNCT05076591 · 2022-06-20

A Phase I Clinical Study for Evaluating the Safety of MASCT-I in Advanced Soild TumorNCT03393416 · 2018-04-19

Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2NCT02952729 · 2016-11-21

A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.NCT00428220 · 2007-07-01

Common interventions

Leading sponsors

BeOne Medicines1 HRYZ Biotech Co.1 ImmuneOnco Biopharmaceuticals (Shanghai) Inc.1 Jiangsu Hansoh Pharmaceutical Co., Ltd.1 Mersana Therapeutics1 Pfizer1 Seagen, a wholly owned subsidiary of Pfizer1 Ulsan University Hospital1 UNICANCER1

Trial status mix

RECRUITING3

COMPLETED2

ACTIVE_NOT_RECRUITING1

SUSPENDED1

TERMINATED1

UNKNOWN1

Phase mix

PHASE15

NA2

PHASE22

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.